Skip to main content
Erschienen in: Der Gynäkologe 6/2016

20.05.2016 | Ultraschall | Leitthema

Der nichtinvasive Pränataltest (NIPT) sinnvoll eingesetzt

verfasst von: Prof. Dr. M. Krapp

Erschienen in: Die Gynäkologie | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Der nichtinvasive Pränataltest (NIPT) ermöglicht eine Entdeckungsrate für das Down-Syndrom von 99,2 % und übertrifft damit das Ersttrimesterscreening (ETS), erfüllt aber nicht die Kriterien für eine vollwertige Diagnostik. Die sonographische Untersuchung des Feten im Rahmen des ETS ermöglicht auch die differenzierte Beurteilung des Feten und ist unverzichtbarer Bestandteil einer vollwertigen Beurteilung des Feten am Ende des ersten Trimenon, da angeborene Fehlbildungen deutlich häufiger sind als chromosomale Aberrationen. Darüber hinaus ermöglicht die Beurteilung sonographischer Zusatzmarker im Rahmen des ETS eine präzise Einordnung in Risikogruppen. Der NIPT hat seine Berechtigung vor allem im intermediären Risikobereich. Die suffiziente Interpretation des Befunds und die Beratung der Schwangeren sind entscheidend für die richtige Auswahl diagnostischer Schritte.
Literatur
1.
Zurück zum Zitat Akolekar R, Beta J, Picciarelli G, Ogilvie C, D’Antonio F (2015) Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 45:16–26CrossRefPubMed Akolekar R, Beta J, Picciarelli G, Ogilvie C, D’Antonio F (2015) Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 45:16–26CrossRefPubMed
2.
Zurück zum Zitat Becker R, Wegner RD (2006) Detailed screening for fetal anomalies and cardiac defects at the 11–13-week scan. Ultrasound Obstet Gynecol 27:613–618CrossRefPubMed Becker R, Wegner RD (2006) Detailed screening for fetal anomalies and cardiac defects at the 11–13-week scan. Ultrasound Obstet Gynecol 27:613–618CrossRefPubMed
3.
Zurück zum Zitat Canick JA, Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE (2013) The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. Prenat Diagn 33:1–8CrossRef Canick JA, Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE (2013) The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. Prenat Diagn 33:1–8CrossRef
6.
Zurück zum Zitat Eiben B, Merz E, Thode C (2011) Der neue Algorithmus der FMF-Deutschland. Frauenarzt 52:490–492 Eiben B, Merz E, Thode C (2011) Der neue Algorithmus der FMF-Deutschland. Frauenarzt 52:490–492
7.
Zurück zum Zitat Ekelund CK, Jorgensen FS, Petersen OB, Sundberg K, Tabor A (2008) Impact of a new national screening policy for Down’s syndrome in Denmark: population based cohort study. BMJ 337:2547–2554CrossRef Ekelund CK, Jorgensen FS, Petersen OB, Sundberg K, Tabor A (2008) Impact of a new national screening policy for Down’s syndrome in Denmark: population based cohort study. BMJ 337:2547–2554CrossRef
8.
Zurück zum Zitat Ghaffari SR, Tahmasebpour AR, Jamal A, Hantoushzadeh S, Eslamian L, Marsoosi V, Fattahi F, Rajaei M, Niroomanesh S, Borna S, Beigi A, Khazardoost S, Saleh-Gargari S, Rahimi-Sharbaf F, Farrokhi B, Bayani N, Tehrani SE, Shahsavan K, Farzan S, Moossavi S, Ramezanzadeh F, Dastan J, Rafati M (2012) First-trimester screening for chromosomal abnormalities by integrated application of nuchal translucency, nasal bone, tricuspid regurgitation and ductus venosus flow combined with maternal serum free ß‑hCG and PAPP-A: a 5‑year prospective study. Ultrasound Obstet Gynecol 39:528–534CrossRefPubMed Ghaffari SR, Tahmasebpour AR, Jamal A, Hantoushzadeh S, Eslamian L, Marsoosi V, Fattahi F, Rajaei M, Niroomanesh S, Borna S, Beigi A, Khazardoost S, Saleh-Gargari S, Rahimi-Sharbaf F, Farrokhi B, Bayani N, Tehrani SE, Shahsavan K, Farzan S, Moossavi S, Ramezanzadeh F, Dastan J, Rafati M (2012) First-trimester screening for chromosomal abnormalities by integrated application of nuchal translucency, nasal bone, tricuspid regurgitation and ductus venosus flow combined with maternal serum free ß‑hCG and PAPP-A: a 5‑year prospective study. Ultrasound Obstet Gynecol 39:528–534CrossRefPubMed
9.
Zurück zum Zitat Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH (2015) Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 45:249–266CrossRefPubMed Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH (2015) Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 45:249–266CrossRefPubMed
10.
Zurück zum Zitat Gil MM, Revello R, Poon LC, Akolekar R, Nicolaides KH (2016) Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results from first-trimester combined test. Ultrasound Obstet Gynecol 47:45–52CrossRefPubMed Gil MM, Revello R, Poon LC, Akolekar R, Nicolaides KH (2016) Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results from first-trimester combined test. Ultrasound Obstet Gynecol 47:45–52CrossRefPubMed
11.
Zurück zum Zitat Grati FR, Malvestiti F, Ferreira JC, Bajaj K, Gaetani E, Agrati C, Grimi B, Dulcetti F, Ruggeri AM, Toffol S De, Maggi F (2014) Wapner R, Gross S, Simoni G. Fetoplacental mosaicism: potential implications for false-positive and false-negative noninvasive prenatal screening results. Genet Med 16:620–624CrossRefPubMed Grati FR, Malvestiti F, Ferreira JC, Bajaj K, Gaetani E, Agrati C, Grimi B, Dulcetti F, Ruggeri AM, Toffol S De, Maggi F (2014) Wapner R, Gross S, Simoni G. Fetoplacental mosaicism: potential implications for false-positive and false-negative noninvasive prenatal screening results. Genet Med 16:620–624CrossRefPubMed
12.
Zurück zum Zitat Grati FR, Bajaj K, Malvestiti F, Agrati C, Grimi B, Malvestiti B, Pompilii E, Maggi F, Gross S, Simoni G, Ferreira JC (2015) The type of feto-placental aneuploidy detected by cfDNA testing may infuence the choice of confirmatory diagnostic procedure. Prenat Diagn 35:994–998CrossRefPubMed Grati FR, Bajaj K, Malvestiti F, Agrati C, Grimi B, Malvestiti B, Pompilii E, Maggi F, Gross S, Simoni G, Ferreira JC (2015) The type of feto-placental aneuploidy detected by cfDNA testing may infuence the choice of confirmatory diagnostic procedure. Prenat Diagn 35:994–998CrossRefPubMed
13.
Zurück zum Zitat Gross SJ, Stosic M, McDonald-McGinn DM, Bassett AS, Norvez A, Dhamankar R, Kobara K, Kirkizlar E, Zimmermann B, Wayham N, Babiarz JE, Ryan A, Jinnett KN, Demko Z, Benn P (2016) Clinical experience with single-nucleotide polymorphismbased non-invasive prenatal screening for 22q11.2 deletion syndrome. Ultrasound Obstet Gynceol. doi:10.1002/uog.15754 (in press) Gross SJ, Stosic M, McDonald-McGinn DM, Bassett AS, Norvez A, Dhamankar R, Kobara K, Kirkizlar E, Zimmermann B, Wayham N, Babiarz JE, Ryan A, Jinnett KN, Demko Z, Benn P (2016) Clinical experience with single-nucleotide polymorphismbased non-invasive prenatal screening for 22q11.2 deletion syndrome. Ultrasound Obstet Gynceol. doi:10.1002/uog.15754 (in press)
14.
Zurück zum Zitat Hagen A, Entezami M, Gasiorek-Wiens A, Albig M, Becker R, Knoll U, Stumm M, Wegner RD (2011) The impact of first trimester screening and early fetal anomaly scan on invasive testing rates in women with advanced maternal age. Ultraschall Med 32:302–306CrossRefPubMed Hagen A, Entezami M, Gasiorek-Wiens A, Albig M, Becker R, Knoll U, Stumm M, Wegner RD (2011) The impact of first trimester screening and early fetal anomaly scan on invasive testing rates in women with advanced maternal age. Ultraschall Med 32:302–306CrossRefPubMed
15.
Zurück zum Zitat Hsiao C, Cheng P, Shaw SSW, Hsu J, Chen R, Tseng Y, Chu W (2014) Extended first-trimester screening using multiple sonographic markers and maternal serum biochemistry: A five-year prospective study. Fetal Diagn Ther 35:296–301PubMed Hsiao C, Cheng P, Shaw SSW, Hsu J, Chen R, Tseng Y, Chu W (2014) Extended first-trimester screening using multiple sonographic markers and maternal serum biochemistry: A five-year prospective study. Fetal Diagn Ther 35:296–301PubMed
16.
Zurück zum Zitat Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH (2009) Prospective validation of first-trimester combined screening for trisomy 21. Ultrasound Obstet Gynecol 34:14–18CrossRefPubMed Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH (2009) Prospective validation of first-trimester combined screening for trisomy 21. Ultrasound Obstet Gynecol 34:14–18CrossRefPubMed
17.
Zurück zum Zitat Kagan KO, Staboulidou I, Syngelaki A, Cruz J, Nicolaides KH (2010) The 11–13-week scan: diagnosis and outcome of holoprosencephaly, exomphalos and megacystis. Ultrasound Obstet Gynecol 36:10–14CrossRefPubMed Kagan KO, Staboulidou I, Syngelaki A, Cruz J, Nicolaides KH (2010) The 11–13-week scan: diagnosis and outcome of holoprosencephaly, exomphalos and megacystis. Ultrasound Obstet Gynecol 36:10–14CrossRefPubMed
18.
Zurück zum Zitat Kagan KO, Staboulidou I, Cruz J, Wright D, Nicolaides KH (2010) Two-stage first-trimester screening for trisomy 21 by ultrasound assessment and biochemical testing. Ultrasound Obstet Gynecol 36:542–547CrossRefPubMed Kagan KO, Staboulidou I, Cruz J, Wright D, Nicolaides KH (2010) Two-stage first-trimester screening for trisomy 21 by ultrasound assessment and biochemical testing. Ultrasound Obstet Gynecol 36:542–547CrossRefPubMed
19.
Zurück zum Zitat Krapp M, Ludwig A, Axt-Fliedner R, Kreiselmaier P (2011) First trimester fetal echocardiography: Which planes and defects can be displayed during the daily routine in a prenatal medicine unit? Ultraschall Med 32:362–366CrossRefPubMed Krapp M, Ludwig A, Axt-Fliedner R, Kreiselmaier P (2011) First trimester fetal echocardiography: Which planes and defects can be displayed during the daily routine in a prenatal medicine unit? Ultraschall Med 32:362–366CrossRefPubMed
20.
Zurück zum Zitat Krapp M, Thomsen Y, Ludwig A, Enzensberger C, Kreiselmaier P (2016) Indications for fetal invasive procedures at the end of an era. Ultraschall Med. doi:10.1055/s-0034-1399290 (in press)PubMed Krapp M, Thomsen Y, Ludwig A, Enzensberger C, Kreiselmaier P (2016) Indications for fetal invasive procedures at the end of an era. Ultraschall Med. doi:10.1055/s-0034-1399290 (in press)PubMed
21.
Zurück zum Zitat Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O (2005) Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: Results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 25:221–226CrossRefPubMed Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O (2005) Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: Results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 25:221–226CrossRefPubMed
22.
Zurück zum Zitat Revello R, Sarno L, Ispas A, Akolekar R, Nicolaides KH (2016) Screening for trisomies by cell-free DNA testing of maternal blood: consequences of failed result. Ultrasound Obstet Gynecol. doi:10.1002/uog.15851 (in press) Revello R, Sarno L, Ispas A, Akolekar R, Nicolaides KH (2016) Screening for trisomies by cell-free DNA testing of maternal blood: consequences of failed result. Ultrasound Obstet Gynecol. doi:10.1002/uog.15851 (in press)
23.
Zurück zum Zitat Rossi AC, Prefumo F (2013) Accuracy of ultrasonography at 11–14 weeks of gestation for detection of fetal structural anomalies: A systematic review. Obstet Gynecol 122:1160–1167CrossRefPubMed Rossi AC, Prefumo F (2013) Accuracy of ultrasonography at 11–14 weeks of gestation for detection of fetal structural anomalies: A systematic review. Obstet Gynecol 122:1160–1167CrossRefPubMed
24.
Zurück zum Zitat Schmid M, Klaritsch P, Arzt W, Burkhardt T, Duba HC, Häusler M, Hafner E, Lang U, Pertl B, Speicher M, Steiner H, Tercanli S, Merz E, Heling KS, Eiben B (2015) Drei Länder – Empfehlung zumEinsatz von Nicht-invasiven pränatalenTests (NIPT) zur Analyse der zellfreien DNA (cfDNA) im mütterlichen Blut zum Screening auf fetale Chromosomenstörungen in der klinischen Praxis. Ultraschall Med 36:507–510CrossRefPubMed Schmid M, Klaritsch P, Arzt W, Burkhardt T, Duba HC, Häusler M, Hafner E, Lang U, Pertl B, Speicher M, Steiner H, Tercanli S, Merz E, Heling KS, Eiben B (2015) Drei Länder – Empfehlung zumEinsatz von Nicht-invasiven pränatalenTests (NIPT) zur Analyse der zellfreien DNA (cfDNA) im mütterlichen Blut zum Screening auf fetale Chromosomenstörungen in der klinischen Praxis. Ultraschall Med 36:507–510CrossRefPubMed
25.
Zurück zum Zitat Siljee JE, Knegt AC, Knapen MF, Bekker MN, Visser GH, Schielen PC (2014) Positive predictive value for detection of trisomies 21, 18 and 13 and termination of pregnancy rates after referral for advanced maternal age, first trimester combined test or ultrasound abnormalities in a national screening programme (2007–2009). Prenat Diagn 34:259–264CrossRefPubMed Siljee JE, Knegt AC, Knapen MF, Bekker MN, Visser GH, Schielen PC (2014) Positive predictive value for detection of trisomies 21, 18 and 13 and termination of pregnancy rates after referral for advanced maternal age, first trimester combined test or ultrasound abnormalities in a national screening programme (2007–2009). Prenat Diagn 34:259–264CrossRefPubMed
26.
Zurück zum Zitat Snijders RJM, Johnson S, Sebire NJ, Noble PL, Nicolaides KH (1996) First-trimester ultrasound screening for chromosomal defects. Ultrasound Obstet Gynecol 7:216–226CrossRefPubMed Snijders RJM, Johnson S, Sebire NJ, Noble PL, Nicolaides KH (1996) First-trimester ultrasound screening for chromosomal defects. Ultrasound Obstet Gynecol 7:216–226CrossRefPubMed
27.
Zurück zum Zitat Tabor A, Vestergaard CHF, Lidegaard O (2009) Fetal loss rate after chorionic villus sampling and amniocentesis: An 11-year national registry study. Ultrasound Obstet Gynceol 34:19–24CrossRef Tabor A, Vestergaard CHF, Lidegaard O (2009) Fetal loss rate after chorionic villus sampling and amniocentesis: An 11-year national registry study. Ultrasound Obstet Gynceol 34:19–24CrossRef
28.
Zurück zum Zitat Wright D, Wright A, Nicolaides KH (2015) A unified approach to risk assessment for fetal aneuploidies. Ultrasound Obstet Gynecol 45:48–54CrossRefPubMed Wright D, Wright A, Nicolaides KH (2015) A unified approach to risk assessment for fetal aneuploidies. Ultrasound Obstet Gynecol 45:48–54CrossRefPubMed
29.
Zurück zum Zitat Wulff CV, Gerds TA, Rode L, Ekelund CK, Petersen O, Tabor A (2016) Risk of fetal loss associated with invasive testing following combined first-trimester screening for Down syndrome: a national cohort of 147 987 singleton pregnancies. Ultrasound Obstet Gynecol 47:38–44CrossRefPubMed Wulff CV, Gerds TA, Rode L, Ekelund CK, Petersen O, Tabor A (2016) Risk of fetal loss associated with invasive testing following combined first-trimester screening for Down syndrome: a national cohort of 147 987 singleton pregnancies. Ultrasound Obstet Gynecol 47:38–44CrossRefPubMed
Metadaten
Titel
Der nichtinvasive Pränataltest (NIPT) sinnvoll eingesetzt
verfasst von
Prof. Dr. M. Krapp
Publikationsdatum
20.05.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Gynäkologie / Ausgabe 6/2016
Print ISSN: 2731-7102
Elektronische ISSN: 2731-7110
DOI
https://doi.org/10.1007/s00129-016-3886-1

Weitere Artikel der Ausgabe 6/2016

Der Gynäkologe 6/2016 Zur Ausgabe

Das könnte Sie auch interessieren

01.06.2016 | Trisomien | Leitthema

Nichtinvasive pränatale Tests

Überblick über die Grundlagen und den Einsatz der Methoden

12.05.2016 | Trisomien | Leitthema

Nichtinvasive pränatale Tests aus Sicht des Humangenetikers

Möglichkeiten und Grenzen in der täglichen Routine

Open Access 17.05.2016 | Trisomie 21 | Leitthema

Nichtinvasive pränatale Tests in der Zukunft

Ausweitung der Indikationen, Evolution der Untersuchungsplattform und Regionalisierung

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.